N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives

Abstract

Background

Arterial hypertension is a main determinant of arterial remodelling and atherosclerosis. Coronary artery calcium score and carotid intima-media thickness are recognized indices of vascular remodelling. Established biohumoral markers for the diagnosis of atherosclerosis are still lacking in asymptomatic subjects with hypertension.

Objectives

We aimed to test the association of plasma N-terminal pro B-type natriuretic peptide concentrations with either coronary artery calcium score or carotid intima-media thickness in asymptomatic hypertensive subjects.

Methods

We conducted a case–control study on 436 hypertensi.ve and 436 age/sex-matched normotensive subjects from the population of the Montignoso HEart and Lung Project, a community-based study of asymptomatic general population ≥45 years. Subjects underwent N-terminal pro B-type natriuretic peptide measurement, echocardiography and evaluation of coronary artery calcium score and carotid intima-media thickness.

Results

Hypertensive subjects had higher median coronary artery calcium score (60 (interquartile range, 30–112) vs. 15 (interquartile range 3–70) Agatson units, p = 0.007), carotid intima-media thickness (8.6 (interquartile range 7.5–9.1) vs. 7.9 (7.1–8.4) µm, p < 0.001) and indexed left ventricular mass (101 (interquartile range 82–126) vs. 87 (63–91) mg/m2, p = 0.03) than controls, with no differences in left ventricular ejection fraction, diameters, E/E′, left atrial area. N-terminal pro B-type natriuretic peptide concentrations were higher in hypertensive subjects with either coronary artery calcium score (p = 0.008) or carotid intima-media thickness >75th (p < 0.006) percentile and highest in combined coronary artery calcium score/carotid intima-media thickness >75th percentile (p = 0.021). In multivariable analysis, N-terminal pro B-type natriuretic peptide independently predicted either coronary artery calcium score or carotid intima-media thickness >75th percentile, but only in hypertensive subjects (odds ratio = 1.87, 95% confidence interval 1.30–2.74, p = 0.001 and odds ratio = 1.99, 95% confidence interval 1.43–2.76, p = 0.001).

Conclusions

In asymptomatic subjects with hypertension, N-terminal pro B-type natriuretic peptide is a marker of hypertension-mediated preclinical vascular disease.

Keywords

Arterial hypertension natriuretic peptide subclinical atherosclerosis

Get full access to this article

View all access options for this article.

References

Drazner

. The progression of hypertensive heart disease. Circulation 2011; 123: 327–334.

Ghiadoni

Taddei

Virdis

. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32: 25–32.

Megnien

Simon

Lemariey

. Hypertension promotes coronary calcium deposit in asymptomatic men. Hypertension 1996; 27: 949–954.

Jensky

Criqui

Wright

. Blood pressure and vascular calcification. Hypertension 2010; 55: 990–997.

Greenland

LaBree

Azen

. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004; 291: 210–215.

Ali

Rembold

Weaver

. Prediction of major adverse cardiovascular events by age-normalized carotid intimal medial thickness. Atherosclerosis 2006; 187: 186–190.

Wang

Larson

Levy

. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. NEJM 2004; 350: 655–663.

Clerico

Recchia

Passino

. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17–H29.

Casco

Veinot

Kuroski de Bold

. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002; 50: 799–809.

10.

Johnson

Hoagland

Olson

. Endogenous vascular synthesis of B-type and C-type natriuretic peptides in the rainbow trout. Exp Biol 2011; 15: 2709–2717.

11.

Abdullah

Khera

Das

. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 2005; 96: 1284–1289.

12.

Peng

Lin

Zhang

. B-type natriuretic peptides and subclinical target organ damage in essential hypertensive patients. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 2347–2350.

13.

Nishikimi

Yoshihara

Morimoto

. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22–30.

14.

Irzmański

Pawlicki

Charłusz

. Concentration of natriuretic peptides in patients suffering from idiopathic arterial hypertension and left ventricular diastolic dysfunction confirmed by echocardiography. Clin Exp Hypertens 2012; 34: 530–540.

15.

Pauriah

Khan

Lim

. B-type natriuretic peptide is an independent predictor of endothelial function in man. Clin Sci 2012; 123: 307–312.

16.

Masugata

Senda

Inukai

. Association of cardio-ankle vascular index with brain natriuretic peptide levels in hypertension. J Atheroscler Thromb 2012; 19: 255–262.

17.

Wilson

D'Agostino

Levy

. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

18.

Agatston

Janowitz

Hildner

. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832.

19.

Lang

Bierig

Devereux

. American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–1463.

20.

Woodard

Rosado

. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol 2008; 268: 59–93.

21.

Ahluwalia

MacAllister

Hobbs

. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 2004; 99: 83–89.

22.

Curillova

Yaman

Dorbala

. Quantitative relationship between coronary calcium content and coronary flow reserve as assessed by integrated PET/CT imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1603–1610.

23.

Suga

Nakao

Hosoda

. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229–239.

24.

Huelsmann

Neuhold

Resl

. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013; 62: 1365–1372.

25.

Ledwidge

Gallagher

Conlon

. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310: 66–74.

26.

Emdin

Passino

Prontera

. Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. Clin Chem 2007; 53: 1289–1297.